MAGLUMI CMV IgG (CLIA)

INTENDED USE
The kit has been designed for the qualitative determination of CMV IgG in human serum. The test has to be performed on the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI (Including Maglumi 600, Maglumi 1000, Maglumi 1000 Plus, Maglumi 2000, Maglumi 2000 Plus, Maglumi 3000 and Maglumi 4000).

SUMMARY AND EXPLANATION OF THE TEST
Human cytomegalovirus (hCMV) is a member of the Herpetoviridae family and is one of the human herpesviruses pathogenic for man. It is ubiquitous, species-specific and is spread by close human contact. The viral capsid, which has a DNA core, is icosahedral in shape and is formed of 162 capsomers. One or more oval membranes containing lipids surround the capsid. hCMV infection can be primary or secondary. Primary infection may be acquired through different transmission routes and in different periods of life (i.e., congenital and post-natal infections). Following primary infection, hCMV enters a latency phase during which the virus can be found in B lymphocytes. Subsequent reactivation of viral replication (secondary infection) may take place concomitantly with changes in the relationship between host and virus, such as pregnancy, serious illness, immunosuppressive therapy or stress.

Congenital infection is transmitted transplacentally or at birth and can occur even if pregnant women already present antibodies to hCMV (re-infection with exogenous virus). If seronegative women contract primary hCMV infection during pregnancy, sequelae may be abortion, stillbirth or neonatal malformation. This is the case even if the birth of a normal child is possible in almost 50% of maternal infections. The clinical picture of congenital hCMV infection is always severe and includes psychomotor retardation, deafness, retinochoroiditis, microcephaly, hydrocephalus, cardiac disease, hepatitis, hepatosplenomegaly, thrombocytopenia. The mortality rate is quite high. Most individuals (40-90%) acquire primary hCMV infection during childhood or adulthood. Post-natal infections are transmitted through close contact with infected biological fluids (urine, saliva, breast milk, semen, cervical secretions, faeces), infected blood products and, occasionally, organ transplants. In immunocompetent individuals, the clinical picture of post-natal hCMV infection is usually mild or asymptomatic. The commonest signs include fever, malaise, and increased serum transaminase levels without jaundice. By contrast in immunocompromized patients (organ transplant recipients, patients with AIDS, lymphoproliferative diseases or cancer), symptoms may be severe because of disseminated and/or visceral infection, and include splenomegaly, pneumonia, haemolytic anemia, myocarditis and encephalitis. In these patients the disease may be fatal.

The immune response to hCMV involves synthesis of IgM antibodies some weeks after infection by hCMV and, one week later, of IgG antibodies. Levels of IgM to hCMV usually increase for some weeks and decrease slowly thereafter, in four to six months. Occasionally, IgM may circulate for years. Specific IgM assay is instrumental in diagnosing acute hCMV infection, which remains difficult to identify from symptoms alone. However, it is not always possible to distinguish between primary and secondary infection, because reactivation may induce synthesis of IgM in immunocompromized patients. Specific IgG assay is useful in distinguishing subjects who have
acquired the disease from those who have not. This is particularly important in order to adopt suitable prophylaxis in susceptible individuals.

Determination of immune status to hCMV is of particular importance (a) in immunocompromized patients, in whom the disease may have serious consequences; (b) in young fertile or pregnant women, so as to avoid virus transmission to the foetus; (c) in organ transplant recipients and donors and (d) in blood donors. White blood cells, namely polymorphonuclear leucocytes, may carry hCMV which may infect blood or organ recipients.

Detection of IgM to hCMV allows adequate treatment to be administered, as needed. Prophylaxis of hCMV infection may be achieved by administration of high-titered virus-specific immunoglobulin preparations. In addition, overt disease may be treated with specific antiviral agents.

PRINCIPLE OF THE TEST

Indirect immunoluminometric assay;

Mouse anti-human IgG antibody is used to label ABEI, and use purified CMV antigen to coat nano magnetic microbeads. Sample, Calibrator or Control with Buffer (goat Anti-human IgM, goat Anti-human IgA) and nano magnetic microbeads coated with CMV antigen are mixed thoroughly and incubated at 37°C, forming a sandwich; After sediment in a magnetic field, decant the supernatant, then cycle washing for 1 time. Then add ABEI Label, incubation and washing for the 2nd time. Subsequently, the starter reagents are added and a flash chemiluminescent reaction is initiated. The light signal is measured by a photomultiplier as RLU within 3 seconds and is proportional to the concentration of CMV IgG present in samples.

CONT

KIT COMPONENTS

Material Supplies

<table>
<thead>
<tr>
<th>Reagent Integral for 100 determinations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nano magnetic microbeads: TRIS buffer, 1.2%(W/V), 0.2%NaNO₃, coated with purified CMV antigen</td>
</tr>
<tr>
<td>Calibrator Low: bovine serum, 0.2%NaNO₃</td>
</tr>
<tr>
<td>Calibrator High: bovine serum, 0.2%NaNO₃</td>
</tr>
<tr>
<td>Buffer: sheep anti-human IgG, sheep anti-human IgM, containing BSA, 0.2%NaNO₃</td>
</tr>
<tr>
<td>ABEI Label: Mouse anti-human IgG antibody labelled ABEI, containing BSA, 0.2%NaNO₃</td>
</tr>
</tbody>
</table>

All reagents are provided ready-to-use.

Reagent Vials in kit box

| Internal Quality Control: containing BSA, 0.2%NaNO₃, (target value refer to Quality Control Information date sheet) | 2.0ml |

Internal quality control is only applicable with MAGLUMI system. Instructions for use and target value refer to Quality Control Information date sheet. User needs to judge results with their own standards and knowledge.

Accessories Required But Not Provided

| MAGLUMI Reaction Module | REF: 630003 |
| MAGLUMI Starter 1-2 | REF: 130299004M |
| MAGLUMI Wash Concentrate | REF: 130299005M |
| MAGLUMI Light Check | REF: 130299006M |

Please order accessories from SNIBE or our representative.

Preparation of the Reagent Integral

Before the sealing is removed, gentle and careful horizontal shaking of the Reagent Integral is essential (avoid foam formation!)

Remove the sealing and turn the small wheel of the magnetic microbeads compartment to and fro, until the colour of the suspension has changed into brown. Place the Integral into the reagent area and let it stand there for 30 min. During this time, the magnetic microbeads are automatically agitated and completely resuspended.

Do not interchange integral component from different reagents or lots!

Storage and Stability

- Sealed: Stored at 2-8°C until the expiry date.
- Opened: Stable for 4 weeks. To ensure the best kit performance, it is recommended to place opened kits in the refrigerator if it’s not going to be used on board during the next 12 hours.

CALIBRATION AND TRACEABILITY

- Traceability

To perform an accurate calibration, we have provided the test calibrators standardized against the SNIBE internal reference substance. Calibrators in the Reagent Kit are from Fitzgerald.

- 2-Point Recalibration

Via the measurement of calibrators, the predefined master curve is adjusted (recalibrated) to a new, instrument-specific measurement level with each calibration.

- Frequency of Recalibration

- After each exchange of lots (Reagent Integral or Starter Reagents).
- Every week and/or each time a new Integral is used (recommendation).
- After each servicing of the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI.
- If controls are beyond the expected range.
- The room temperature has changed more than 5°C (recommendation)

SPECIMEN COLLECTION AND PREPARATION

Sample material: serum

Collect 5.0ml venous blood into Blood Collection Tube (Tube without anticoagulant or coagulant, Anticoagulation tube with EDTA-K₂ or EDTA-Na₂ can be used. Anticoagulation tube with heparin sodium is not recommended). Standing at room temperature, centrifuging, separating serum part.

The serum sample is stable for up to 12 hours at 2-8°C. If preserved for more than 12 hours, please packed, -20°C can be stored for 30 days.

Avoid repeated freezing and thawing, the serum sample can be only frozen and thawed two times. Stored samples should be thoroughly mixed prior to use (Vortex mixer).

Please ask local representative of SNIBE for more details if you have any doubt.

Vacuum Tubes

(a) Blank tubes are recommended type for collecting samples.
(b) Please ask SNIBE for advice if special additive must be used in sample collecting.

Specimen Conditions

7111303606-V2.3-EN
Do not use specimens with the following conditions:
(a) heated-inactivated specimens;
(b) Cadaver specimens or body fluids other than human serum;
(c) Obvious microbial contamination.

- Use caution when handling patient specimens to prevent cross contamination. Use of disposable pipettes or pipette tips is recommended.
- Inspect all samples for bubbles. Remove bubbles with an applicator stick prior to analysis. Use a new applicator stick for each sample to prevent cross contamination.
- Serum specimens should be free of fibrin, red blood cells or other particulate matter.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the specimen is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results.

**Preparation for Analysis**
- Patient specimens with a cloudy or turbid appearance must be centrifuged prior to testing. Following centrifugation, avoid the lipid layer (if present) when pipetting the specimen into a sample cup or secondary tube.
- Specimens must be mixed thoroughly after thawing by low speed vortexing or by gently inverting, and centrifuged prior to use to remove red blood cells or particulate matter to ensure consistency in the results. Multiple freeze-thaw cycles of specimens should be avoided.
- All samples (patient specimens or controls) should be tested within 3 hours of being placed on board the MAGLUMI System. Refer to the SNIBE service for a more detailed discussion of onboard sample storage constraints.

**Storage**
- If testing will be delayed for more than 8 hours, remove serum from the serum separator, red blood cells or clot. Specimens removed from the separator gel, cells or clot may be stored up to 12 hours at 2-8°C.
- Specimens can be stored up to 30 days frozen at -20°C or colder.

**Shipping**
- Before shipping specimens, it is recommended that specimens be removed from the serum separator, red blood cells or clot. When shipped, specimens must be packaged and labeled in compliance with applicable state, federal and international regulations covering the transport of clinical specimens and infectious substances. Specimens must be shipped frozen (dry ice). Do not exceed the storage time limitations identified in this section of the package insert.

**WARNING AND PRECAUTIONS FOR USERS**

- For use in IN-VITRO diagnostic procedures only.
- Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert.

**Safety Precautions**
- CAUTION: This product requires the handling of human specimens.
- The calibrators in this kit are prepared from bovine serum products. However, because no test method can offer complete assurance that HIV, Hepatitis B Virus or other infectious agents are absent; these reagents should be considered a potential biohazard and handled with the same precautions as applied to any serum or plasma specimen.
- All samples, biological reagents and materials used in the assay must be considered potentially able to transmit infectious agents. They should therefore be disposed of in accordance with the prevailing regulations and guidelines of the agencies holding jurisdiction over the laboratory, and the regulations of each country. Disposable materials must be incinerated; liquid waste must be decontaminated with sodium hypochlorite at a final concentration of 5% for at least half an hour. Any materials to be reused must be autoclaved using an overkill approach. A minimum of one hour at 121°C is usually considered adequate, though the users must check the effectiveness of their decontamination cycle by initially validating it and routinely using biological indicators.
- It is recommended that all human sourced materials be considered potentially infectious and handled in accordance with the OSHA Standard on Bloodborne Pathogens 13. Biosafety Level 214 or other appropriate biosafety practices should be used for materials that contain or are suspected of containing infectious agents.
- This product contains Sodium Azide; this material and its container must be disposed of in a safe way.
- Safety data sheets are available on request.

**Handling Precautions**
- Do not use reagent kits beyond the expiration date.
- Do not mix reagents from different reagent kits.
- Prior to loading the Reagent Kit on the system for the first time, the microbeads requires mixing to re-suspend microbeads that have settled during shipment.
- For microbeads mixing instructions, refer to the KIT COMPONENTS, Preparation of the Reagent Integral section of this package insert.
- To avoid contamination, wear clean gloves when operating with a reagent kit and sample.
- Over time, residual liquids may dry on the kit surface, please pay attention the silicon film still exists on the surface of the kit.
- For a detailed discussion of handling precautions during system operation, refer to the SNIBE service information.

**TEST PROCEDURE**
To ensure proper test performance, strictly adhere to the operating instructions of the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI. Each test parameter is identified via a RFID tag on the Reagent Integral. For further information please refer to the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI Operating Instructions.

| 10μl | Auto dilute-Sample, calibrator |
| 400μl | Cycle washing |
| +200μl | Buffer |
| +20μl | Nano magnetic microbeads |
| 10 min | Incubation |
| +200μl | ABEI Label |
| 400μl | Cycle washing |
| 10 min | Incubation |
| 3 s | Measurement |

* Do not interchange magnetic microbeads from different lots.

**QUALITY CONTROL**
- Observe quality control guidelines for medical laboratories
- Use suitable controls for in-house quality control. Controls should be run at least once every 24 hours when the test is in use, once per reagent kit and after every calibration. The control intervals should be adapted to each laboratory’s individual requirements. Values obtained should fall within the defined ranges. Each laboratory should establish guidelines for corrective measures to be taken if values fall outside the range.
LIMITATIONS OF THE PROCEDURE

1) Limitations
Use CMV IgG value as a kind of auxiliary material for other testing data when in diagnosis. Assay results should be utilized in conjunction with other clinical and laboratory data to assist the clinician in making individual patient management decisions. A skillful technique and strict adherence to the instructions are necessary to obtain reliable results. Bacterial contamination of samples or repeated freeze-thaw cycles may affect the test results. Assay results should be utilized in conjunction with other clinical and laboratory data to assist the clinician in making individual patient management decisions.

2) Interfering Substances
No interference with test results is seen by concentrations of bilirubin \(<0.4\text{mg/mL}\), haemoglobin \(\leq10\text{mg/mL}\). Triglycerides \(\leq20\text{mg/mL}\).

3) HAMA
Patient samples containing human anti-mouse antibodies (HAMA) may give falsely elevated or decreased values. Although HAMA-neutralizing agents are added, extremely high HAMA serum concentrations may occasionally influence results.

RESULTS

1) Calculation of Results
The analyzer automatically calculates the CMV IgG concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in AU/ml. For further information please refer to the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI Operating Instructions.

2) Interpretation of Results
Results obtained with the MAGLUMI CMV IgG assay can be interpreted as follows:
- Non-reactive: A result less than 2 AU/ml (< 2 AU/ml) is considered to be negative.
- Reactive: A result greater than or equal to 2 AU/ml is (≥ 2 AU/ml) considered to be positive.
Since there is no CMV IgG international standard material yet, different IVD manufacturer have different traceability chain. Therefore results from assays of other manufacturers cannot be used interchangeably.

PERFORMANCE CHARACTERISTICS

1) Precision
Intra-assay coefficient of variation was evaluated on 3 different levels of control serum repeatedly measured 20 times in the same run, calculating the coefficient of variation.

<table>
<thead>
<tr>
<th>Level</th>
<th>Mean(AU/ml)</th>
<th>SD(AU/ml)</th>
<th>CV%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.71</td>
<td>0.10</td>
<td>5.91</td>
</tr>
<tr>
<td>2</td>
<td>7.41</td>
<td>0.41</td>
<td>5.54</td>
</tr>
<tr>
<td>3</td>
<td>17.89</td>
<td>0.99</td>
<td>5.55</td>
</tr>
</tbody>
</table>

Inter-assay coefficient of variation was evaluated on three batches of kits. Repeatedly measured 3 different levels of control serum 21 times, calculating the coefficient of variation.

<table>
<thead>
<tr>
<th>Level</th>
<th>Mean(AU/ml)</th>
<th>SD(AU/ml)</th>
<th>CV%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.68</td>
<td>0.16</td>
<td>9.42</td>
</tr>
<tr>
<td>2</td>
<td>7.25</td>
<td>0.64</td>
<td>8.84</td>
</tr>
<tr>
<td>3</td>
<td>18.24</td>
<td>1.60</td>
<td>8.77</td>
</tr>
</tbody>
</table>

2) Analytical Sensitivity
The sensitivity is defined as the concentration of CMV IgG equivalent to the mean RLU of 20 replicates of the zero standard plus two standard deviations corresponding to the concentration from the standard curve. The sensitivity is typically less than 0.25 AU/ml.

3) Specificity
The specificity of the CMV IgG assay system was assessed by measuring the apparent response of the assay to various potentially cross reactive analytes. When CMV IgM, Rubella IgG, Rubella IgM, Toxo IgG, Toxo IgM, HSV-1/2 IgG, HSV-1/2 IgM separately reach a concentration of 30AU/ml measured CMV IgG is negative. No cross reaction with the IgG or IgM antibody of HAV, HBV, HCV, HIV, syphilis, EBV. The ELISA diagnosed RF or ANA positive, which is non CMV infected sample, this reagent’s determination results show negative.

4) Recovery
Consider calibrator high of known concentration as a sample, dilute it by 1:2 ratio with diluents, and measure its diluted concentration for 10 times. Then calculate the recovery of measured concentration and expected concentration. The recovery should be within 90% -110%.

<table>
<thead>
<tr>
<th>Expected</th>
<th>Mean Measuring</th>
<th>Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.0 AU/ml</td>
<td>10.0 AU/ml</td>
<td>102%</td>
</tr>
</tbody>
</table>

REFERENCES